Arterial Stiffness and Pulse Wave Velocity: An Adjunct Risk Marker, Not a Standalone Screen

What is established: the measurement itself

Carotid-femoral pulse wave velocity, the reference method for aortic stiffness, is measured with applanation tonometry that times a pressure wave traveling between the carotid and femoral arteries. A European expert consensus group standardized the technique, the distance measurement conventions, and reference values across laboratories, and the method has since been used in tens of thousands of research participants across cohort studies worldwide.[3]

That consensus and standardization work is about the test itself, not about any specific clinical use of the number it produces. A stiffer aorta is a real, measurable, reproducible physiological finding. Whether measuring it changes what a physician should tell a patient, or do for a patient, is a separate question that has to be answered with its own evidence.[3]

What the evidence for risk prediction actually shows

The strongest evidence for pulse wave velocity as a risk marker comes from two large syntheses of longitudinal data. A meta-analysis pooling 17 studies and roughly 15,900 subjects followed for an average of 7.7 years found aortic stiffness was associated with roughly double the risk of cardiovascular events, cardiovascular death, and all-cause mortality in the highest stiffness groups compared with the lowest.[2]

A separate individual-participant-data meta-analysis, pooling raw data from 17,635 subjects across multiple prospective cohorts rather than just published summary statistics, found that adding aortic pulse wave velocity to the Framingham Risk Score and standard risk factors improved prediction of future cardiovascular events beyond those factors alone. This is a meaningfully stronger form of evidence than pooling published study averages, because it lets researchers test the same statistical model consistently across all the original patient-level data.[1]

Put together, this is a reasonably solid case that arterial stiffness carries independent prognostic information. It is not, on its own, evidence that measuring it and acting on it changes what happens to a patient. Improving a statistical prediction model and improving patient outcomes are different claims, and the field has historically been quick to blur that distinction.[1][2]

The trap: better prediction is not the same as better treatment

This is the point patients most often misunderstand about any new risk marker, and arterial stiffness is a clean example of it. A number can correlate with future risk and still be useless, or even actively unhelpful, as a target to chase with treatment.

What remains uncertain

No randomized trial has shown that using pulse wave velocity to guide treatment decisions reduces cardiovascular events or death, and the one trial designed specifically to test this, SPARTE, was negative on its primary endpoint despite achieving its physiological goal of lower stiffness and blood pressure. That is an important negative finding, not a footnote, and it should temper any claim that arterial stiffness testing changes management in a way proven to help patients.[4]

The prediction evidence itself also has real limits. Both large syntheses are observational, meaning they show association and improved statistical prediction, not causation. Measurement is not fully interchangeable across devices and techniques in routine clinical use outside the research cohorts where the consensus protocol was followed carefully, and the populations studied were predominantly higher cardiovascular risk cohorts rather than broad, low-risk populations seeking preventive screening.[1][3]

There is also no validated pathway showing that identifying elevated stiffness in an otherwise low-risk, asymptomatic person should trigger a specific treatment change beyond what standard risk factor management would already recommend. The marker adds information to a risk model; it has not been shown to add a distinct, separately effective intervention.[4]

What this means for you

AION treats arterial stiffness measurement as one input into a physician's broader cardiovascular risk assessment, never as a standalone screen and never presented to a patient as a number to chase down through treatment. The evidence supports its use to refine risk estimation alongside blood pressure, lipids, and other standard factors, particularly when a physician is deciding how much weight to put on borderline findings elsewhere.

Given the SPARTE result, AION does not use pulse wave velocity as a treatment target in itself, and does not promise that normalizing a stiffness number will change cardiovascular outcomes. Where a result is abnormal, the physician's response is to reassess the same established risk factors, blood pressure, lipids, glucose control, that already have trial evidence behind treating them, not to invent a new stiffness-specific protocol. There is no fixed AION protocol for this test; findings are interpreted case by case by the treating physician.[4]